Piper Jaffray Companies reiterated their overweight rating on shares of Celyad SA (NASDAQ:CYAD) in a report issued on Monday morning. Piper Jaffray Companies currently has a $74.00 target price on the stock.
Several other analysts have also issued reports on CYAD. ValuEngine upgraded shares of Celyad SA from a sell rating to a hold rating in a research note on Thursday, June 29th. BidaskClub lowered shares of Celyad SA from a buy rating to a hold rating in a research note on Tuesday, July 11th.
Shares of Celyad SA (NASDAQ CYAD) opened at 60.30 on Monday. The firm has a 50-day moving average of $56.51 and a 200-day moving average of $56.51. Celyad SA has a 52 week low of $16.31 and a 52 week high of $64.75. The firm’s market cap is $574.36 million.
ILLEGAL ACTIVITY NOTICE: “Celyad SA (CYAD) Rating Reiterated by Piper Jaffray Companies” was originally posted by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://baseballnewssource.com/markets/celyad-sa-cyad-rating-reiterated-by-piper-jaffray-companies/1704066.html.
About Celyad SA
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with our FREE daily email newsletter.